<DOC>
	<DOCNO>NCT01406132</DOCNO>
	<brief_summary>The objective study evaluate pharmacokinetics , particular route excretion extent metabolism ASP015K single oral dose 14C-labeled ASP015K .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics ASP015K Healthy Male Subjects</brief_title>
	<detailed_description>Eligible subject admit clinical research unit confine minimum 8 day .</detailed_description>
	<criteria>The subject body weight least 45 kg body mass index ( BMI ) 18 32 kg/m2 , inclusive The subject nonsmoker least 3 month prior checkin The subject agree sexual abstinence , surgically sterile ( documentation provide healthcare professional ) , use medically acceptable method prevent pregnancy study period The subject 's clinical laboratory test result within normal limit The subject medically healthy , clinically significant medical history abnormalities The subject history clinically significant gastrointestinal , cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease malignancy exclude nonmelanoma skin cancer The subject history malabsorption syndrome previous gastrointestinal surgery could affect drug absorption metabolism The subject recent history irregular defecation , constipation diarrhea The subject history drug alcohol abuse , positive urine screen alcohol drug abuse/illegal drug The subject treatment prescription drug complementary alternative medicine ( CAM ) within 14 day prior study drug administration , counter ( OTC ) medication within past week The subject has/had symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 1 week prior clinic check The subject know positive human immunodeficiency virus ( HIV ) antibody The subject positive test hepatitis C antibody , positive test hepatitis B antigen ( HBsAg ) The subject positive tuberculosis ( TB ) Quantiferon Gold test The subject receive experimental agent within 30 day five halflives , whichever longer , prior study drug administration The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission The subject exposure significant radiation ( eg , serial xray compute tomography scan , barium meal , current employment job require radiation exposure monitoring ) within 12 month prior checkin The subject participate radiolabeledstudy within last 6 month , participate one radiolabeled study within past 12 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>ASP015K</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>